Abstract: A system and method for mechanical processing of cells includes using a frame (102) forming an inlet channel (104), an outlet channel (106), and a processing chamber (108) fluidly connected between the inlet and outlet channels, wherein the processing chamber includes an anvil surface (112) formed on the frame. A hammer (110) mounted on the frame has a processing surface disposed in opposed relation to the anvil surface. The hammer is configured to move relative to the anvil surface. An actuator connected to the frame and operably associated with the hammer operates to move the hammer relative to the anvil surface and in close proximity to the anvil surface, wherein the hammer operates between a retracted position in which the processing surface is at a distance from the anvil surface, and an extended position in which the processing surface abuts the anvil surface.

Abstract: This disclosure is directed to a methods and systems for establishing a long-range quantum link in a quantum communication network and for improving connection rate of the quantum link. The quantum link is established across multiple quantum repeaters relying on quantum entanglement swap operations in the multiple quantum repeaters. The methods and systems use nested connection loops that are started as soon as quantum repeater resources become available.

Abstract: Provided are a superlattice structure including a two-dimensional material and a device including the superlattice structure. The superlattice structure may include at least two different two-dimensional (2D) materials bonded to each other in a lateral direction, and an interfacial region of the at least two 2D materials may be strained. The superlattice structure may have a bandgap adjusted by the interfacial region that is strained. The at least two 2D materials may include first and second 2D materials. The first 2D material may have a first bandgap in an intrinsic state thereof. The second 2D material may have a second bandgap in an intrinsic state thereof. An interfacial region of the first and second 2D materials and an adjacent region may have a third bandgap between the first bandgap and the second bandgap.

Abstract: Multi-layer materials and related systems and methods are generally described.

Abstract: Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13R?2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13R?2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).

Abstract: Metal-organic layers (MOLs) and metal-organic nanoplates (MOPs) comprising photosensitizers are described. The MOLs and MOPs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOL or MOP. Also described are methods of using MOLs and MOPs in photodynamic therapy, X-ray induced photodynamic therapy (X-PDT), radiotherapy (RT), radiodynamic therapy, or in radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator.

Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

Abstract: Provided herein are compositions comprising Oxalobacter formigenes (Of)-derived factors and variants and fragments thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto.

Abstract: Methods and systems are disclosed for sensing an environment electric field. In one exemplary implementation, a method includes disposing a sensor in the environment, wherein the sensor comprising a crystalline lattice and at least one optically-active defect in the crystalline lattice; pre-exciting the crystalline lattice to prepare at least one defect in a first charge state using a first optical beam at a first optical wavelength; converting at least one defect from the first charge state to a second charge state using a second optical beam at a second optical wavelength; monitoring a characteristics of photoluminescence emitted from the defect during or after the conversion of the at least one defect from the first charge state to the second charge state; and determining a characteristics of the electric field in the environment according to the monitored characteristics of the photoluminescence.

Abstract: Embodiments concern methods and composition related to anergic T-cells in patients, such as cancer patients.

Abstract: Materials are provided for use as active emissive layers in organic electronic devices such as light-emitting filed effect transistors. Light-emitting transistors (LET) are an alternative to light-emitting diodes and have several important benefits, however, materials developed specifically for LET are quite scarce. Herein a new family of materials is disclosed that has been developed specifically for LET.

Abstract: A system, computer readable storage medium and method for generating protein sequences, includes an encoder configured to encode a plurality of input protein sequences onto a latent space distribution, and an autoregressive generator configured to decode the latent space distribution to generate new protein sequences different from the input protein sequences. The system is trained with a loss function that includes reconstruction loss and aa mutual information maximization term.

Abstract: Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an ? chain (such as SEQ ID NO: 2) and a ? chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR ? and/or ? chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR ? chain and the TCR ? chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR ? chain and the TCR ? chain, and administering a composition comprising the modified T cells to the subject.

Abstract: The disclosure is directed to devices, systems, and methods for a generation of a decoherence-protected subspace in a quantum system. The decoherence-protected subspace provides the quantum system with reduced sensitivity to environmental magnetic, electric, and thermal noises. Quantum information operation based on the quantum system can be performed while this decoherence-protected subspace is maintained.

Abstract: In aspects, the invention provides a method of treating or preventing a nidovirus or picornavirus infection in a subject, the method comprising administering to a subject in need thereof an effective amount of an active agent of butamben, butylparaben, conivaptan, amphotericin B, pentoxyverine, lapatinib, vilazodone, imatinib (STI571), benztropine, raloxifene, solifenacin, retapamulin, bafetinib (INNO-406), imipramine, trimipramine, tolterodine, clomipramine, velpatasvir, cediranib (AZD2171), azelastine, desloratadine, nortriptyline, propafenone, mebeverine, elbasvir, cepharanthine, flupenthixol dihydrochloride, or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., Pseudomonas aeruginosa, by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.

Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

Abstract: In aspects, the disclosure provides a method of differentiating a malignant tumor from a non-malignant tumor in a mammal having a tumor comprising determining in a sample from the mammal the level of one or more of: (1) transthyretin (TTR) RNA or protein, (2) dual oxidase 2 (DUOX2) RNA or protein, and (3) G-protein coupled receptor 179 (GPR179) RNA or protein.

Abstract: A method and system that harnesses extremely weak Kerr-type nonlinearities in a single driven cavity to deterministically generate single photon Fock states, and more general photon-blockaded states are disclosed. The disclosed scheme is effective even for nonlinearities that are much smaller than photonic loss in the cavity. The disclosed scheme generates photon-blockade states that are non-Gaussian, exhibit a sharp cut-off in their photon number distribution, and can be arbitrarily close to, for example, a single-photon Fock state. This scheme relies only standard linear and parametric drives, and are hence compatible with a variety of different photonic platforms.

Abstract: Aspects of the disclosure relate to the finding that certain modeling of single-cell RNA-sequencing (scRNA-seq) data can provide cell profiles of the analyzed cell population. Certain aspects use algorithms including topic modeling, burst modeling, and data integration to determine the profiles. To apply RNA velocity to more general systems, including immune response studies, aspects herein concern a new approach that can infer the cells and genes associated with distinct active processes via probabilistic topic modeling and uses the results to estimate process-specific velocity parameters.